Nebraska Legislature Bill LB984

Nebraska 2023-2024 Regular Session

• Introduced: 1/5/24
• Refer: 1/9/24
• Failed: 4/18/24

Caption

Prohibit certain actions relating to distribution of drugs by 340B entities

Impact

The passage of LB984 would signify significant changes for 340B entities, particularly non-profit hospitals and clinics that rely on this program to provide discounted medications to low-income patients. By imposing restrictions on how drugs can be distributed, the bill aims to enhance accountability while fostering transparency in operations. Proponents believe that these changes will ultimately protect vulnerable patient populations and ensure that the benefits of the 340B program are utilized effectively and ethically.

Summary

LB984 primarily seeks to prohibit certain actions related to the distribution of drugs by entities operating under the 340B Drug Pricing Program. This legislation aims to address concerns regarding how these entities distribute medications, especially in terms of ensuring equitable patient access and compliance with federal regulations. The intent behind the bill is to create clearer guidelines for 340B entities to follow and to mitigate potential abuses of the program that could impact patient care and healthcare affordability.

Contention

The bill has sparked debate among various stakeholders in the healthcare sector. Supporters argue that LB984 is a necessary step to prevent misuse of the 340B program and to ensure that drug savings are passed on to the patients who need them most. However, opponents, including some healthcare providers and advocacy groups, contend that the proposed restrictions may hinder the ability of 340B entities to effectively serve their communities. They are concerned that the limitations might lead to disruptions in drug access for patients who rely on these services, particularly in underrepresented and underserved areas.